These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29734173)

  • 21. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
    Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
    Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
    Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM
    HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. suPAR in cardiovascular disease.
    Montecillo J; Pirker T; Pemberton C; Chew-Harris J
    Adv Clin Chem; 2024; 121():89-131. PubMed ID: 38797545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
    Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
    Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
    Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
    J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Indoxyl Sulfate on Coronary Plaques in Patients on Hemodialysis.
    Asami M; Tanabe K; Ito S; Yoshida E; Aoki J; Tanimoto S; Horiuchi Y; Yoshida M
    Int Heart J; 2018 May; 59(3):489-496. PubMed ID: 29743417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
    Zhang Q; Li L; Chen H; Zhang G; Zhu S; Kong R; Chen H; Wang G; Sun B
    J Clin Lab Anal; 2020 Mar; 34(3):e23097. PubMed ID: 31774228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
    Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
    Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease.
    Goodchild TT; Li Z; Lefer DJ
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
    Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
    Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
    [No Abstract]   [Full Text] [Related]  

  • 34. Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.
    Huang Y; Zhou H; Wu Y; Yang Y; Li W; Lu J; Hu Y
    Dis Markers; 2017; 2017():4719403. PubMed ID: 29109596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
    Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA
    J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.
    Törnkvist PBS; Haupt TH; Rasmussen LJH; Ladelund S; Toft U; Pisinger C; Eugen-Olsen J
    Br J Nutr; 2019 Mar; 121(6):699-708. PubMed ID: 30626457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
    Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A
    Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
    Chenevier-Gobeaux C; Lemarechal H; Doumenc B; Peschanski N; Claessens YE; Borderie D; Ray P
    Clin Biochem; 2021 Jun; 92():19-24. PubMed ID: 33662350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
    Ishikawa H; Izumiya Y; Shibata A; Ichikawa Y; Yamaguchi T; Yamaguchi Y; Kitada R; Iwata S; Ehara S; Tomita S; Hanatani A; Yoshiyama M
    Heart Vessels; 2020 May; 35(5):681-688. PubMed ID: 31741050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.